Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $859898.0.

  • BioRestorative Therapies' Accounts Payables rose 11423.59% to $859898.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $859898.0, marking a year-over-year increase of 11423.59%. This contributed to the annual value of $483070.0 for FY2024, which is 15506.76% up from last year.
  • BioRestorative Therapies' Accounts Payables amounted to $859898.0 in Q3 2025, which was up 11423.59% from $609931.0 recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' Accounts Payables peaked at $859898.0 during Q3 2025, and registered a low of $50827.0 during Q4 2021.
  • For the 5-year period, BioRestorative Therapies' Accounts Payables averaged around $317908.4, with its median value being $238281.5 (2021).
  • Per our database at Business Quant, BioRestorative Therapies' Accounts Payables crashed by 8800.94% in 2021 and then surged by 28716.89% in 2022.
  • BioRestorative Therapies' Accounts Payables (Quarter) stood at $50827.0 in 2021, then skyrocketed by 236.24% to $170902.0 in 2022, then grew by 10.82% to $189389.0 in 2023, then skyrocketed by 155.07% to $483070.0 in 2024, then surged by 78.01% to $859898.0 in 2025.
  • Its last three reported values are $859898.0 in Q3 2025, $609931.0 for Q2 2025, and $599500.0 during Q1 2025.